Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 10/20 | 0.90 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 0.90 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.90 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.90 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.90 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.90 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.90 |
| ▸ | RHOC | P08134 | 1/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.90 |
| ▸ | THRB | P10828 | 1/20 | 0.90 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.90 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.90 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.77 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.77 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.77 |
| ▸ | PDE6D | O43924 | 3/20 | 0.69 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4787702 | 1.00 | HMGCR (0.90) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL27952561 | 0.99 | HMGCR (0.88) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL10108890 | 0.95 | HMGCR (0.85) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL4428234 | 0.95 | HMGCR (0.85) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL15492882 | 0.95 | HMGCR (0.85) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL820410 | 0.95 | HMGCR (0.85) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL8257670 | 0.95 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL6266705 | 0.95 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL21637576 | 0.95 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL3056792 | 0.95 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | claimed |
| CN-111184717-A | Composition containing mixture of pyrrolyl dihydroxy heptanoic acid derivatives and use thereof | 黄泳华 | 2020-05-22 | — | — | CN | claimed |
| CN-111110854-A | Composition comprising a histamine release-promoting substance and an inhibitory compound | 黄泳华 | 2020-05-08 | — | — | CN | claimed |
| CN-111068064-A | Composition comprising fatty acid or derivative thereof and dihydroxyheptanoic acid derivative | 黄泳华 | 2020-04-28 | — | — | CN | claimed |
| WO-2005023305-A2 | MODULATING CELL ACTIVITY BY USING AN AGENT THAT REDUCES THE LEVEL OF CHOLESTEROL WITHIN A CELL | INPHARMATICA LIMITED (GB) | 2005-03-17 | — | — | WO | claimed |
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | disclosed |
| CN-111184717-A | Composition containing mixture of pyrrolyl dihydroxy heptanoic acid derivatives and use thereof | 黄泳华 | 2020-05-22 | — | — | CN | disclosed |
| CN-111110854-A | Composition comprising a histamine release-promoting substance and an inhibitory compound | 黄泳华 | 2020-05-08 | — | — | CN | disclosed |
| US-20140081033-A1 | Novel Crystalline Form of Atorvastatin Hemi-calcium Salt, Hydrate Thereof, And Method of Producing The Same | KYONGBO PHARM (KR) | 2014-03-20 | — | — | US | disclosed |
| US-20110064816-A1 | ATORVASTATIN COMPOSITIONS | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-03-17 | — | — | US | disclosed |
| US-20110064816-A1 | ATORVASTATIN COMPOSITIONS | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-03-17 | — | — | US | disclosed |
| US-20090216029-A1 | PROCESS FOR THE PRODUCTION OF ATORVASTATIN CALCIUM IN AMORPHOUS FORM | RANBAXY LABORATORIES LIMITED (IN) | 2009-08-27 | — | — | US | disclosed |
| US-20090186834-A1 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090005321-A1 | Phenylazetidinone Derivatives | MICROBIA, INC. (US) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090216029-A1 | PROCESS FOR THE PRODUCTION OF ATORVASTATIN CALCIUM IN AMORPHOUS FORM | HMGCR, CACYBP, SARAF | HMGCR 1/4885SLCO1B1 433/4885ABCB11 2194/4885 |
| US-20140081033-A1 | Novel Crystalline Form of Atorvastatin Hemi-calcium Salt, Hydrate Thereof, And Method of Producing The Same | HMGCR, DHCR7, LIPA | HMGCR 1/4885SLCO1B1 200/4885ABCB11 589/4885 |
| US-20090186834-A1 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | NPC1L1, CYP46A1, NPC1 | HMGCR 12/4885SLCO1B1 157/4885ABCB11 20/4885 |
| US-20110064816-A1 | ATORVASTATIN COMPOSITIONS | HMGCR, PCSK9, LIPA | HMGCR 1/4885SLCO1B1 48/4885ABCB11 122/4885 |
| US-20090005321-A1 | Phenylazetidinone Derivatives | TYR, AAAS, FANCD2 | HMGCR 2474/4885SLCO1B1 2341/4885ABCB11 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.